PRIMEVAX IMMUNO ONCOLOGY INC has a total of 30 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, EPO (European Patent Office) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are SHANGHAI SUNWAY BIOTECH CO LTD, TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO LTD and VAXIN INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | China | 4 | |
#4 | Canada | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Mexico | 2 | |
#7 | Australia | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Lyday Bruce W | 27 |
#2 | Chen Tony | 12 |
#3 | Bruce W Lyday | 2 |
#4 | Tony Chen | 1 |
Publication | Filing date | Title |
---|---|---|
SG11201912163WA | Compositions and methods for cancer therapy with dengue virus and dendritic cells | |
EP3565567A1 | Compositions and methods for therapy with dengue virus | |
EP3541417A1 | Combination immunotherapies for treatment of cancer | |
CA2999881A1 | Compositions and methods for producing dendritic cells | |
CN107921063A | For the composition and method using dengue virus and the conjoint therapy of dendritic cells |